81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)

M.A Bittoni,S Keeping,D.P Carbone,J.E Park,A.T.H Nguyen,K Toor,N Petruski-Ivleva,A.K Vadanahalli Shankar,G Konidaris

doi:10.1016/j.iotech.2023.100553

81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)

M.A Bittoni, S Keeping + Show 7 more

https://doi.org/10.1016/j.iotech.2023.100553

Copy DOI

Journal: Immuno-Oncology and Technology

Publication Date: Dec 1, 2023

Affiliation: MD Precision (Canada), Sanofi (United Kingdom), Sanofi (United States), The Ohio State University, AVEO Oncology (United States)

#Metastatic Non-squamous Non-small Cell Lung #Docetaxel Regimens + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)

Full Text